Skip to main content
Natco Pharma Ltd. logo

Natco Pharma Ltd. — Investor Relations & Filings

Ticker · NATCOPHARM ISIN · INE987B01026 LEI · 33580086GIBRWXSNGG39 BSE.NS Manufacturing
Open in API
Filings indexed 1,708 across all filing types
Latest filing 2019-05-27 Regulatory Filings
Country IN India
Listing BSE.NS NATCOPHARM

About Natco Pharma Ltd.

https://www.natcopharma.co.in/

Natco Pharma Ltd. is a vertically integrated organization focused on the development, manufacturing, and marketing of complex generics and active pharmaceutical ingredients (APIs). The company specializes in niche therapeutic areas, maintaining a leadership position in oncology and a significant presence in specialty segments such as hepatology, cardiology, and diabetology. Natco is recognized for its expertise in high-barrier-to-entry products, including complex oral solids and injectables. Its business model emphasizes research and development to deliver affordable versions of life-saving medicines globally. With a robust portfolio of finished dosage formulations and a strong supply chain for APIs, the company serves diverse international markets, including North America, Europe, and emerging economies, through strategic partnerships and direct distribution channels.

Recent filings

Filing Released Lang Actions
Record date fixed as 7th June, 2019 for Payment of third Interim Dividend
Regulatory Filings
2019-05-27 English
Change in Auditors
Regulatory Filings Classification · 95% confidence The document is a formal announcement dated 27th May 2019 from NATCO Pharma Limited addressed to stock exchanges. It reports the outcome of a Board Meeting where the Board approved the audited financial results for the year ended 31st March 2019, declared an interim dividend, recommended appointment of new statutory auditors, and approved the notice for the upcoming Annual General Meeting. The document includes a declaration under listing regulations and an annexure detailing the appointment of new auditors. The content is primarily an announcement of decisions made by the Board rather than the full audited financial report itself. The document length is about 5085 characters, which is relatively short and consistent with an announcement rather than a full annual report or audit report. Therefore, this document fits best as a Regulatory Filing (RNS) since it is an official regulatory announcement about board decisions, financial results approval, and auditor appointment, but does not contain the full annual report or detailed financial statements themselves.
2019-05-27 English
Financial Result Updates
Regulatory Filings
2019-05-27 English
Appointment of Statutory Auditors
Regulatory Filings
2019-05-27 English
Results For the Financial Year 18-19
Regulatory Filings
2019-05-27 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a notification about an upcoming earnings call scheduled for May 28, 2019, to discuss the financial results for Q4FY19 and FY19. It includes details about the call timing, participants, and dial-in information. The document does not contain actual financial results or detailed financial statements but rather serves as an announcement for the earnings call event. According to the classification rules, such documents are classified as Call Transcript (CT) only if they contain the full transcript of the call. Since this is only an announcement of the call, it does not qualify as a transcript. It is also not an Earnings Release (ER) because it does not present financial highlights or results, only the call details. The best fitting category is Regulatory Filings (RNS) as a general regulatory announcement about the earnings call event.
2019-05-22 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.